Investors

Press Releases

ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

May 3, 2019

Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

May 1, 2019

Geneva, Switzerland and Boston, MA –May 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…

Read more

ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

April 29, 2019

Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

April 1, 2019

Geneva, Switzerland and Boston, MA – April 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

March 29, 2019

Geneva, Switzerland and Boston, MA – March 29, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

Nolasiban Set to Revolutionise Fertility: Interview in ‘The Times’ with ObsEva CEO, Ernest Loumaye

March 27, 2019

Read more

ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

March 13, 2019

Geneva, Switzerland and Boston – March 13, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…

Read more

ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update

March 5, 2019

Major 2018 Accomplishments Driven by Positive Clinical Trial Results –Significant increase in rates of pregnancy and live birth (up to…

Read more

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

February 27, 2019

Geneva, Switzerland and Boston, MA –February 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

February 22, 2019

Geneva, Switzerland and Boston, MA – February 22, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.

 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue